Edwards Lifesciences Co. (NYSE:EW) Receives $82.10 Consensus Price Target from Analysts

Shares of Edwards Lifesciences Co. (NYSE:EW) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-five analysts that are presently covering the company, MarketBeat.com reports. Thirteen analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $82.10.

EW has been the topic of several recent research reports. Canaccord Genuity Group lowered their price objective on shares of Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. Evercore ISI decreased their target price on shares of Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating on the stock in a research note on Thursday, July 25th. Daiwa Capital Markets upgraded shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, July 25th. Finally, Oppenheimer reduced their price objective on shares of Edwards Lifesciences from $100.00 to $90.00 and set an “outperform” rating on the stock in a research report on Thursday, July 25th.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $66.81 on Friday. The firm’s 50 day moving average price is $74.75 and its 200-day moving average price is $84.13. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $40.26 billion, a PE ratio of 28.80, a price-to-earnings-growth ratio of 2.92 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter in the prior year, the business earned $0.66 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. Equities research analysts expect that Edwards Lifesciences will post 2.7 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,250 shares of company stock valued at $1,321,988. 1.29% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. DSM Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $28,000. Crewe Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $28,000. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $29,000. Riverview Trust Co acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $34,000. Finally, Pingora Partners LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.